Cognitive dysfunction in Moyamoya disease: latest developments and future directions
Xilong Wang(Zhaotong University), Rong Wang(Capital Medical University), J Zhang(Zhaotong University), Yanru Wang(Capital Medical University), Shihao He(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhenyu Zhou(World Wide Web Consortium), Ziqi Liu(Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital)
Cited by 6
Related Papers
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
|New England Journal of Medicine|2015|241
Characteristics of cognitive impairment in adult asymptomatic moyamoya disease
|BMC Neurology|2020|39
Association between white matter impairment and cognitive dysfunction in patients with ischemic Moyamoya disease
|BMC Neurology|2020|30
Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease
|Stroke|2023|30
A 90-Day Prognostic Model Based on the Early Brain Injury Indicators after Aneurysmal Subarachnoid Hemorrhage: the TAPS Score
|Translational Stroke Research|2022|28